Pedro Garbes
Overview
Explore the profile of Pedro Garbes including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
669
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Palmer C, Scallan C, Kraemer Tardif L, Kachura M, Rappaport A, Koralek D, et al.
Nat Commun
. 2023 Jun;
14(1):3274.
PMID: 37280238
SARS-CoV-2 has resulted in high levels of morbidity and mortality world-wide, and severe complications can occur in older populations. Humoral immunity induced by authorized vaccines wanes within 6 months, and...
2.
Levin M, Ustianowski A, Thomas S, Templeton A, Yuan Y, Seegobin S, et al.
Clin Infect Dis
. 2022 Nov;
76(7):1247-1256.
PMID: 36411267
Background: This phase 3 trial assessed AZD7442 (tixagevimab/cilgavimab) for post-exposure prophylaxis against symptomatic coronavirus disease 2019 (COVID-19). Methods: Adults without prior severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection or...
3.
Montgomery H, Hobbs F, Padilla F, Arbetter D, Templeton A, Seegobin S, et al.
Lancet Respir Med
. 2022 Jun;
10(10):985-996.
PMID: 35688164
Background: Early intramuscular administration of SARS-CoV-2-neutralising monoclonal antibody combination, tixagevimab-cilgavimab, to non-hospitalised adults with mild to moderate COVID-19 has potential to prevent disease progression. We aimed to evaluate the safety...
4.
Levin M, Ustianowski A, De Wit S, Launay O, Avila M, Templeton A, et al.
N Engl J Med
. 2022 Apr;
386(23):2188-2200.
PMID: 35443106
Background: The monoclonal-antibody combination AZD7442 is composed of tixagevimab and cilgavimab, two neutralizing antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that have an extended half-life and have been...
5.
Biswal S, Borja-Tabora C, Vargas L, Velasquez H, Alera M, Sierra V, et al.
Lancet
. 2020 Mar;
395(10234):1423-1433.
PMID: 32197105
Background: A substantial unmet need remains for safe and effective vaccines against dengue virus disease, particularly for individuals who are dengue-naive and those younger than 9 years. We aimed to...
6.
Saez-Llorens X, Tricou V, Yu D, Rivera L, Tuboi S, Garbes P, et al.
Lancet Infect Dis
. 2017 Apr;
17(6):615-625.
PMID: 28365225
Background: Dengue is the most common mosquito-borne viral disease in human beings, and vector control has not halted its spread worldwide. A dengue vaccine for individuals aged 9 years and...
7.
Dayan G, Arredondo J, Carrasquilla G, Deseda C, Dietze R, Luz K, et al.
Am J Trop Med Hyg
. 2015 May;
93(1):18-23.
PMID: 26013373
To prepare for a Phase III dengue vaccine efficacy trial, 20 investigational sites were selected for this observational study to identify dengue infections in a closed cohort (N = 3,000...
8.
Dayan G, Garbes P, Noriega F, de Sadovsky A, Rodrigues P, Giuberti C, et al.
Am J Trop Med Hyg
. 2013 Nov;
89(6):1058-1065.
PMID: 24189367
Immunogenicity and safety of a recombinant, live-attenuated, tetravalent dengue disease vaccine (CYD-TDV) was evaluated in children/adolescents in Brazil. In this observer-blind, placebo-controlled, phase II single-center study, children/adolescents (ages 9-16 years)...
9.
Wallace D, Canouet V, Garbes P, Wartel T
Curr Opin Virol
. 2013 Jun;
3(3):352-6.
PMID: 23747120
Dengue is a potentially fatal viral disease for which treatment is limited to supportive care, and prevention and control are based on mosquito vector control programs. It is the fastest...